A study of a new drug for advanced solid tumors with TP53 Y220C mutation
Part of Cancer, Digestive system, Hormones & metabolism, Lungs & breathing, Skin, Women’s health & pregnancy clinical trials.
This trial tests a new drug (called LG00313112) for people with advanced solid tumors that have a specific genetic change called TP53 Y220C. The drug aims to target this change and may help slow or stop cancer growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older
- You have a type of advanced cancer that has a specific gene change called TP53 Y220C
- Your cancer has gotten worse despite treatment, or you can't take the standard treatments
- You have tumors that can be measured on scans (RECIST criteria)
- You are physically able to care for yourself (ECOG performance status 0-1)
- Your organs (like liver, kidneys, and bone marrow) are working well enough
- You don't have certain exclusions like unstable brain metastases, serious heart problems, or active infections
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study tests PC14586 (rezatapopt) in people with advanced or metastatic solid cancers that carry a specific TP53 mutation called Y220C. It mainly looks at safety and how well the treatment may work, sometimes combined with pembrolizumab.
This trial tests a new type of therapy (NT-175) for people with certain advanced cancers that have a specific genetic change. It might help if your tumor has the TP53 R175H mutation and you have the HLA-A*02:01 immune marker.
This trial tests a new drug called CLSP-1025 for people with advanced solid tumors that have a specific change in the p53 gene (R175H). The drug targets this change to help fight the cancer.
This trial tests a new drug, GV20-0251, for people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and helpful.
This trial tests a new study drug, GV20-0251, for people with advanced solid tumors that no longer respond to standard therapies. It aims to see if the drug can shrink tumors or slow their growth.
This trial tests a personalized cell therapy called TP53 R248Q TCR-T for people with advanced solid tumors that have a specific genetic change (TP53 R248Q mutation). The treatment uses your own immune cells modified to attack cancer cells, and may be an option if standard treatments are no longer working.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.